Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction

Journal of Clinical Lipidology

Volumn 6, Issue 2, 2012, Pages 180-191

  Toth, Peter P ^a   Ballantyne, Christie M ^b   Davidson, Michael H ^c   Tomassini, Joanne E ^d   Ramey, Dena Rosen ^d   Neff, David ^d   Tershakovec, Andrew M ^d   Hu, X Henry ^d   Tunceli, Kaan ^d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ENHANCE; Ezetimibe simvastatin; LDL C; Statin

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; LONGITUDINAL STUDY; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ATHEROSCLEROSIS; AZETIDINES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SIMVASTATIN; TIME FACTORS; YOUNG ADULT;

EID: 84862827717     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.11.007     Document Type: Article

References (45)

1. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
2. H.E. Bays, D. Neff, J.E. Tomassini, and A.M. Tershakovec Ezetimibe: cholesterol lowering and beyond Expt Rev Cardiovasc Ther 6 2008 447 470
3. P.P. Toth, A. Catapano, J.E. Tomassini, and A.M. Tershakovec Update on the efficacy and safety of combination ezetimibe + statin therapy Clin Lipidol 5 2010 665 684
4. Vytorin [product insert]. N. Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2010.
5. J.J.P. Kastelein, F. Akdim, and E.S.G. Stroes Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443 (Pubitemid 351482735)
6. J.J. Kastelein, S.I. van Leuven, and L. Burgess Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630 (Pubitemid 46631671)
7. Carotid atorvastatin study in hyperlipidemia post-menopausal women: a randomized evaluation of atorvastatin versus placebo (Cashmere). NCT#00163163. Pfizer PhRMA Web Synopsis Protocol A2581051. Final Report. Available at: http://clinicaltrials.gov/ct2/show/NCT00163163. Accessed December 7, 2011.
8. S. van Wissen, T.J. Smilde, and M.D. Trip Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia Am J Cardiol 95 2005 264 266 (Pubitemid 40092097)
9. P.P. Toth, and K.A. Maki Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: should ezetimibe move to the "back of the line" as a therapy for dyslipidemia? J Clin Lipidol 2 2008 313 317
10. M.H. Davidson Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications Cleve Clin J Med 75 2008 479 496
11. Crestor (rosuvastatin calcium) tablets [package insert]. Wilmington, DE: AstraZeneca; 2011.
12. Lescol/Lescol XL (fluvastatin) [package insert]. E. Hanover, NJ: Novartis Pharmaceuticals Corp.; 2011.
13. Pravachol [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2011.
14. Zocor (simvastatin) tablets [package insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2010.
15. Mevacor [product insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2010.
16. Zetia [product insert]. N. Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2011.
17. Lipitor (atorvastatin calcium) tablets [package insert]. New York, NY: Parke-Davis; 2009.
18. J.M. Drazen, J.A. Jarcho, and S. Morrissey Cholesterol lowering and ezetimibe N Engl J Med 358 2008 1507 1508 (Pubitemid 351482747)
19. B.G. Brown, and A.J. Taylor Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 358 2008 1504 1507 (Pubitemid 351482746)
20. U.S. Food and Drug Administration. Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor). January 8, 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm079524.htm. Accessed December 7, 2011.
21. American Heart Association. Statement from the American Heart Association on ENHANCE study results. 2008. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm079524.htm.
22. J.L. Fleg, M. Mete, and B.V. Howard Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial J Am Coll Cardiol 52 2008 2198 2205
23. A. Meaney, G. Ceballos, and J. Asbun The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study J Clin Pharmacol 49 2009 838 847
24. National Institutes of Health. NIH stops clinical trial on combination cholesterol treatment. Available at: http://www.nih.gov/news/health/may2011/ nhlbi-26.htm. Accessed December 7, 2011.
25. National Heart Lung, and Blood Institute. Niacin Plus Statin to Prevent Vascular Events. 2005. Available at: http://clinicaltrials.gov/show/NCT00120289. Accessed December 7, 2011.
26. J.G. Robinson, and M. Davidson Is it over for ezetimibe? Exp Rev Cardiovasc Ther 6 2008 781 783
27. University of Oxford. Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). Available at: http://clinicaltrials.gov/show/ NCT00461630. Accessed December 7, 2011.
28. D. Hunninghake, W. Insull, and P. Toth Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively Atherosclerosis 158 2001 407 416 (Pubitemid 32913651)
29. H.N. Ginsberg, M.B. Elam, and L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
30. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592 (Pubitemid 33126837)
31. P.P. Toth Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs Drugs 70 2010 1363 1379
32. K. Tunceli, S.G. Sajjan, and D.R. Ramey Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients J Clin Lipidol 4 2010 491 500
33. H.D. Aronow, G. Hess, J. Hill, A. Kuznik, and L.Z. Liu Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol Am J Ther 17 2010 167 175
34. D. Atar, R. Carmena, and P. Clemmensen Clinical review: impact of statin substitution policies on patient outcomes Ann Med 41 2009 242 256
35. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
36. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681
37. M. Briel, A.J. Nordmann, and H.C. Bucher Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses Curr Opin Lipidol 16 2005 601 605 (Pubitemid 43012155)
38. A.L. Catapano, M.H. Davidson, and C.M. Ballantyne Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients Curr Med Res Opin 22 2006 2041 2053 (Pubitemid 44663409)
39. D.P. Mikhailidis, G.C. Sibbring, and C.M. Ballantyne Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy Curr Med Res Opin 23 2007 2009 2026 (Pubitemid 47300401)
40. D.P. Mikhailidis, R.W. Lawson, and A.L. McCormick Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis Curr Med Res Opin 27 2011 1191 1210
41. R.M. Califf, Y. Lokhnygina, and C.P. Cannon An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J 159 2010 705 709
42. C.P. Cannon, R.P. Guigliano, M.A. Blazing IMPROVE-IT investigators Design and Rationale of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome Am Heart J 156 2008 826 832
43. C. Baigent, M.J. Landray, and C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetmibie in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial Lancet 377 2011 2181-1292
44. A.B. Rossebo, T.R. Pedersen, and K. Boman Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 2008 1343 1356
45. I. Holme, K. Boman, and P. Brudi Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial Am J Cardiol 105 2010 1802 1808